Company Overview
The Leader in Personalized Anti-Cancer Therapy (“ACT”) and Cool Laser Therapy (“CLT”)
Theralase® was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics.
With our multi-discipline experience in physics, engineering, medicine, biology, chemistry, immunology, pharmaceutical drug design, finance, business development, sales, marketing and clinical study coordination, Theralase® is staffed with the talent to drive the next level of technology for personalized healthcare in oncology and pain.
Striving to continuously improve the quality of life for those afflicted with cancer and pain. Theralase®’s research, development and commercialization activities focus on safely and effectively treating oncological and pain-related conditions. Serving our corporate mandate to “Destroying Cancer at the Speed of Light®” and “Healing Pain at the Speed of Light®”.
Founded in 1994, Theralase®’s operations are divided into two main divisions: the Cool Laser Therapy (“CLT”) division focused on the research, development, production and distribution of medical laser technologies for healing pain and also researching, developing and commercializing medical laser technologies for the activation of Photo Dynamic Compounds (“PDCs”) in the Anti-Cancer Therapy (“ACT”) division and the ACT division focused on the destruction of cancer, bacteria and viruses.
Anti-Cancer Therapy Division
Theralase®’s ACT division combines Photo Dynamic Compounds (“PDCs”) with medical laser technologies safely and effectively destroy cancer, bacteria and viruses, while stimulating the immune system.
Cool Laser Therapy Division
Theralase®’s CLT division focuses on the research, development, production and distribution of Cool Laser Therapy products, Health Canada and FDA approved to eliminate knee pain and when used off-label to eliminate pain, reduce inflammation and accelerate tissue healing in numerous nerve, muscle and joint conditions.
Company Overview
Our People
Theralase® accomplishes its mandate of “Destroying Cancer at the Speed of Light®” and “Healing Pain at the Speed of Light®” by researching, developing and commercializing high-quality, cutting edge technology through our scientific, medical, engineering teams completing world-class preclinical and clinical research in each division. Theralase® searches for and hires experts in their respective field both as employees and consultants.
Our History
For over 25 years, the Theralase® team has been dedicated to researching, developing, manufacturing and distributing high-quality, cutting-edge medical laser technologies to healthcare practitioners to heal their patient’s conditions at an affordable price.
Working at Theralase®
Theralase® is dedicated to providing a stimulating work environment that offers growth opportunities, employee benefits and exciting challenges to develop your career to the next level.
Latest press-releases
Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically
Press ReleaseJune 19, 2024 - Rutherrin®, has demonstrated an ability to provide a complete response in a Non-Small Cell Lung Cancer (“NSCLC”) animal model....
Rutherrin® Increases Efficacy of Immunotherapy Preclinically
Press ReleaseJune 18, 2024 - Rutherrin®, in preclinical research, has demonstrated an ability to increase the efficacy of immunotherapy....
Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase®
Press ReleaseJune 14, 2024 - Reminder Notice of Annual General and Special Meeting on June 19, 2024 at 4:30 pm after the formal part of the meeting a virtual zoom presentation will follow at 5:30 pm...
Rutherrin® Increases Efficacy of Chemotherapy
Press ReleaseJune 12, 2024 - Rutherrin® has been proven in preclinical studies to enhance the efficacy of chemotherapy and reduce multidrug resistance....
Ruvidar Enhances Efficacy of Cancer Drug
Press ReleaseJune 10, 2024 - Ruvidar™, in combination with Bacillus Calmette-Guérin (BCG), significantly enhances the cancer cell-killing efficacy compared to BCG or Ruvidar™ alone, even without light activation....
Theralase® Successfully Destroys Lung Cancer
Press ReleaseJune 6, 2024 - Rutherrin®, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer (“NSCLC”)....
Theralase® Technology Effective in Virus Inactivation
Press ReleaseJune 4, 2024 - Theralase's lead compound, Ruvidar, has been proven effective in the inactivation of various viruses. The research was completed at the laboratory of Kevin Coombs, Ph.D., University of Manitoba in conjunction with...
Theralase® Release’s 1Q2024 Financial Statements
Press ReleaseMay 30, 2024 - Theralase releases the Company's unaudited interim consolidated 1Q2024 Financial Statements...
Theralase® Expands Clinical Team
Press ReleaseMay 2, 2024 - Theralase expands its clinical team with the hiring of two Clinical Research Associates....
Theralase® Closes $CAN 750,000 Non-Brokered Private Placement
Press ReleaseApril 24, 2024 - Theralase closes Non-Brokered Private Placement of units for gross proceeds of $CAN 750,200....
AS SEEN ON
